Form 4: BioCardia Director Acquires Stock Options

Andrew Scott Blank, a director at BioCardia, Inc., was granted stock options to purchase 829 shares of common stock at an exercise price of $2.65 on October 11, 2024.

Summary

• On October 11, 2024, Andrew Scott Blank, a director of BioCardia, Inc., acquired stock options.
• The options grant him the right to purchase 829 shares of BioCardia's common stock at an exercise price of $2.65 per share.
• The options vest and become exercisable on October 11, 2025, contingent upon Blank's continued service to the company.
• Following this transaction, Blank directly owns 3,313 shares of BioCardia's common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• Shareholders may view the stock option grant as a sign of alignment between management and shareholder interests.

Key Dates

Keywords

stock options, director, BCDA, BioCardia, Form 4, beneficial ownership